Ivabradin Teva (Ivabradine Hydrochloride)

Ivabradin Teva acts on the cardiac conduction system to reduce heart rate, making it useful in several cardiovascular conditions.

• Chronic stable angina: decreases the frequency of angina attacks and improves exercise capacity by lowering myocardial oxygen demand.
• Heart failure (NYHA class II‑III): reduces resting heart rate, which can improve symptoms, increase exercise tolerance, and potentially reduce hospitalizations in patients with reduced ejection fraction.
• Ischemic heart disease: assists in heart‑rate control to limit ischemic episodes and may complement other anti‑anginal therapies.
• Beta‑blocker intolerance: offers an alternative mechanism to lower heart rate when beta‑blockers are contraindicated or not tolerated.

• Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the primary pacemaker of the heart. By inhibiting this mixed sodium‑potassium inward current, the drug slows spontaneous depolarization, leading to a reduction in heart rate without affecting myocardial contractility or blood pressure. The effect is dose‑dependent and reversible upon discontinuation. Consequently, ivabradine provides a targeted approach to heart‑rate control that is independent of beta‑adrenergic pathways.

Ivabradin Teva may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Bradycardia: resting heart rate may fall below 50 bpm.
• Visual disturbances (phosphenes): transient luminous phenomena, especially in low‑light conditions.
• Headache: mild to moderate intensity.
• Dizziness or vertigo: sensation of light‑headedness.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Severe bradycardia with syncope: may require medical intervention.
• Atrial fibrillation: irregular heart rhythm that can be symptomatic.
• Hypotension: marked drop in blood pressure leading to dizziness.

When prescribing Ivabradin Teva, clinicians should observe several precautionary measures to ensure patient safety.

• Monitor heart rate: ensure resting heart rate is ≥50 bpm before initiation and regularly during therapy.
• Avoid in severe hepatic impairment: reduced metabolism may increase drug exposure.
• Caution in sick sinus syndrome: risk of excessive bradycardia.
• Do not combine with strong CYP3A4 inhibitors: may raise plasma concentrations.
• Pregnancy and lactation: safety not established; use only if potential benefit justifies risk.
• Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradin Teva can interact with other medicines, altering its plasma levels or combined cardiac effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine concentrations.
• Concomitant use with other heart‑rate‑lowering agents (beta‑blockers, digoxin, diltiazem): can cause excessive bradycardia.
• QT‑prolonging drugs (e.g., sotalol, amiodarone): may increase risk of arrhythmias.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may raise levels modestly.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Antidepressants affecting serotonin (e.g., sertraline): may increase incidence of visual disturbances.